Vinflunine in the treatment of advanced bladder cancer

Expert Review of Anticancer Therapy

Volumn 11, Issue 1, 2011, Pages 13-20

  Mamtani, Ronac ^a   Vaughn, David J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

bladder cancer; second line; transitional cell carcinoma of the urothelium; urothelial carcinoma; vinflunine

Indexed keywords

4 O DEACETYL VINFLUNINE; ANTIMITOTIC AGENT; DRUG METABOLITE; NAVELBINE; UNCLASSIFIED DRUG; VINBLASTINE; VINFLUNINE;

ABDOMINAL PAIN; ADVANCED BLADDER CANCER; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLADDER CANCER; BREAST CANCER; CONSTIPATION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; KIDNEY DISEASE; LUNG NON SMALL CELL CANCER; MALIGNANT MESOTHELIOMA; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSORY NEUROPATHY; STOMATITIS; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 78650429254     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.196     Document Type: Review

References (69)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225-249 (2009).
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 46(4), 765-781 (2010).
3. Parkin DM. The global burden of urinary bladder cancer. Scand. J. Urol. Nephrol. Suppl. 218, 12-20 (2008).
4. Stein JP, Lieskovsky G, Cote R. Radical cystectomy in the treatment of invasive bladder cancer: long term results in 1,054 patients. J. Clin. Oncol. 19(3), 666-675 (2001).
5. Loehrer PJ Sr, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma. J. Clin. Oncol. 10(7), 1066-1073 (1992).
6. Von der Maase H, Andersen L, Crino L et al. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a Phase II clinical trial. Ann. Oncol. 10(12), 1461-1465 (1999).
7. Moore MJ, Winquist EW, Murray N et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a Phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 17(9), 2876-2881 (1999).
8. Kaufman D, Raghavan D, Carducci M et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J. Clin. Oncol. 18(9), 1921-1927 (2000).
9. Von Der Maase H, Sengelov L, Roberts JT et al. Long term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 23(21), 4602-4608 (2005).
10. Sternberg CN, de Mulder PH, Schornagel JH et al. Randomized Phase II trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J. Clin. Oncol. 19(10), 2638-2648 (2001).
11. Bellmunt J, von der Maase H, Mead GM et al. Randomized Phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy; EORTC30987/Intergroup study. Proc. Am. Soc. Clin. Oncol. 25(Suppl. 18), (2007) (Abstract LBA5030).
12. Von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cnacer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol. 18(17), 2068-2077 (2000).
13. Tu SM, Hossan E, Amato R et al. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J. Urol. 154(5), 1719-1722 (1995).
14. Sweeney CJ, Williams SD, Finch DE et al. A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. Cancer 86(3), 514-518 (1999).
15. De Mulder PH, Theodore C, Sella A et al. Phase II EORTC trial with 5-fuorouracil, cisplatin and interferon-a as second-line treatment of adcanced transitional cell cancer of the urothelial tract. Ann. Oncol. 11(11), 1391-1394 (2000).
16. Sternberg CN, Calabro F, Pizzocaro G et al. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92(12), 2993-2998 (2001).
17. Meluch AA, Greco FA, Burris HA et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a Phase II trial of the Minnie pearl cancer research network. J. Clin. Oncol. 19(12), 3018-3024 (2001).
18. Krege S, Rembrink V, Borgermann C et al. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a Phase 2 study. J. Urol. 165(1), 67-71 (2001).
19. Pagliaro LC, Millikan RE, Tu SM et al. Cisplatin, gemcitabine, ifosfamide as weekly therapy: a feasibility and Phase II study of salvage treatment for advanced transitional cell carcinoma. J. Clin. Oncol. 20(13), 2965-2970 (2002).
20. Di Lorenzo G, Autorino R, Giordano A et al. FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder. Jpn J. Clin. Oncol. 34(12), 747-750 (2004).
21. Vaishampayan UN, Faulkner JR, Small EJ et al. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study. Cancer 104(8), 1627-1632 (2005).
22. Fechner G, Siener R, Reimann M et al. Randomised Phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int. J. Clin. Pract. 60(1), 27-31 (2006).
23. Kouno T, Ando M, Yonemori K et al. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. Eur. Urol. 52(4), 1115-1122 (2007).
24. Lin CC, Hsu CH, Huang CY et al. Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a Phase II study. Anticancer Drugs. 18(4), 487-491 (2007).
25. Soga N, Onishi T, Arima K et al. Paclitaxel carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases. Int. J. Urol. 14(9), 828-832 (2007).
26. Han KS, Joung JY, Kim TS et al. Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy. Br. J. Cancer 98(1), 86-90 (2008).
27. Di Lorenzo G, Montesarchio V, Autorino R et al. Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients. Cancer 115(3), 517-523 (2009).
28. Suyama T, Ueda T, Fukasawa S et al. Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma. Jpn J. Clin. Oncol. 39(4), 244-250 (2009).
29. Albers P, Park SI, Niegisch G et al. Randomized Phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann. Oncol. DOI: 10.1093/annonc/ mdq398 (2010) (Epub ahead of print).
30. Ngan VK, Bellman K, Hill BT et al. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinfunine. Mol. Pharmacol. 60(18), 5045-5051 (2001).
31. Kruczynski A, Colpaert F, Tarayre JP et al. Preclinical in vivo antitumor activity of Vinfunine, a novel fuorinated Vinca alkaloid. Cancer Chemother. Pharmacol. 41, 437-447 (1998).
32. Hill BT, Fiebig HH, Waud WR et al. Superior in vivo experimental antitumour activity of vinfunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur. J. Cancer 35(3), 512-520 (1999).
33. Bonfl RD, Russo DM, Binda MM et al. Higher antitumor activity of vinfunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder. Urol. Oncol. 7(4), 159-166 (2002).
34. Bellmunt J, Delgado FM, George C. Clinical activity of vinfunine in transitional cell carcinoma of the urothelium and other solid tumors. Semin. Oncol. 35(3), 534-543 (2008).
35. Culine S, Theodore C, De Santis M et al. A Phase II study of vinfunine in bladder cancer patients progressing after frst-line platinum-containing regimen. Br. J. Cancer 94(10), 1395-1401 (2006).
36. Vaughn DJ, Srinivas S, Stadler WM et al. Vinfunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large Phase 2 study. Cancer 115(18), 4110-4117 (2009).
37. Bellmunt K, Theodore C, Demkov T et al. Phase III trial of vinfunine plus best supportive care compared with best supportive care alone after a platinum containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol. 27(27), 4454-4461 (2009).
38. Pearce HL. Medicinal chemistry of bisindole alkaloids from Catharanthus. In: The Alkaloids -Antitumor Bisindole Alkaloids from Catharanthus roseus. Brossi A, Suffness M (Eds). Academic Press, CA, USA, 145 (1990).
39. Fahy J, Dufos A, Ribert JP et al. Vinca alkaloids in superacidic media: a method for creatining a new family of antitumor derivatives. J. Am. Chem. Soc. 119, 8576-8577 (1997).
40. Barnett CJ, Cullinan GJ, Gerzon K et al. Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate. J. Med. Chem. 21(1), 88-96 (1978).
41. Kruczynski A, Barret JM, Etievant C et al. Antimitotic and tubulin-interacting properties of vinfunine, a novel fuorinated Vinca alkaloid. Biochem. Pharmacol. 55(5), 635-648 (1998).
42. Ngan VK, Bellman K, Panda D et al. Novel actions of the antitumor drugs vinfunine and vinorelbine on microtubules. Cancer Res. 60(18), 5045-5051 (2000).
43. Okouneva T, Hill BT, Wilson L, Jordan MA. The effects of vinfunine, vinorelbine, and vinblastine on centromere dynamics. Mol. Cancer Ther. 2(5), 427-436 (2003).
44. Kruczynski A, Poli M, Dossi R et al. Anti-angiogenic, vascular disrupting and anti-metastatic activities of vinfunine, the latest vinka alkaloid in clinical development. Eur. J. Cancer 42(16), 2821-2832 (2006).
45. Lobert S, Fahy J, Hill BT et al. Vinca alkaloid-induced tubulin spiral formation correlates with cytotoxicity in the leukemic L 1210 cell line. Biochemistry 39(39), 12053-12062 (2000).
46. Jordan MA, Horwitz SB, Lobert S et al. Exploring the mechanisms of action of the novel microtubule inhibitor vinfunine. Semin. Oncol. 35(3 Suppl. 3), S6-S12 (2008).
47. Jean-Decoster C, Brichese L, Barret JM et al. Vinfunine, a new Vinca alkaloid: cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells. Anticancer Drugs. 10(6), 537-543 (1999).
48. Etievant C, Kruczynski A, Barret JM et al. Markedly diminished drug resistance-inducing properties of vinfunine (20́,20́-difuoro- 3́,4́-dihydrovinorelbine) relative to vinorelbine, identifed in murine and human tumour cells in vivo and in vitro. Cancer Chemother. Pharmacol. 48(1), 62-70 (2001).
49. Bennouna J, Fumoleau P, Armand JP et al. Phase I and pharmacokinetic study of the new Vinca alkaloid vinfunine administered as a 10 minute infusion every 3 weeks in patients with advanced solid tumours. Ann. Oncol. 14(4), 630-637 (2003).
50. Johnson P, Geldart T, Fumoleau P et al. Phase I study of vinfunine administered as a 10 minute infusion on days 1 and 8 every 3 weeks. Invest. New Drugs 24(3), 223-231 (2006).
51. Focan CN, Van Heugen J-C, Kreutz F et al. Vinfunine metabolism and disposition in cancer patients. Proc. Am. Soc. Clin. Oncol. 21 (2002) (Abstract 495).
52. Paule, B. Saliba F, Gil-Delgado M et al. Phase I and pharmacokinetic (PK) dose-adjusted study of IV vinfunine (VFL) in cancer patients with liver dysfunction (LD): pharmacokinetic results. ASCO Meeting Abstracts (2007) (Abstract 2523).
53. Bajorin DF, Dodd PM, Mazumdar M et al. Long term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J. Clin. Oncol. 17(10), 3173-3181 (1999).
54. Bellmunt J, Choueiri TK, Fougeray R et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J. Clin. Oncol. 28(11), 1850-1855 (2010).
55. Nguyen PL, Swanson PE, Jaszcz W et al. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am. J. Clin. Pathol. 101(2), 166-176 (1994).
56. Hussain MH, MacVicar GR, Petrylak DP et al. Trastuzumab, paclitaxel, carboplatin, and gemcitbaine in advanced human epidermal growth factor receptor-2/ neu-positive urothelial carcinoma: results of a multicenter Phase II National Cancer Institute trial. J. Clin. Oncol. 25(16), 2218-2224 (2007).
57. Dreicer R, Li H, Stein M et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 115(18), 4090-4095 (2009).
58. Gallagher DJ, Milowsky MI, Gerst SR et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J. Clin. Oncol. 28(8), 1373-1379 (2010).
59. Bradley D, Daignault S, Smith DC et al. Maintenance sunitinib postchemotherapy in patients with adcanced urothelial carcinoma: a randomized placebo controlled Phase II trial. J. Clin. Oncol. 27(Suppl. 15), (2009) (Abstract 5073).
60. Witte RS, Elson P, Bono B et al. Eastern Cooperative Oncology Group Phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J. Clin. Oncol. 15(2), 589-593 (1997).
61. Lorusso V, Pollera CF, Antimi M et al. A Phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur. J. Cancer 34(8), 1208-1212 (1998).
62. McCaffrey JA, Hilton S, Mazumdar M et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J. Clin. Oncol. 15(5), 1853-1857 (1997). (Pubitemid 27209514)
63. Vaughn DJ, Manola J, Dreicer R et al. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. Cancer 95(5), 1022-1027 (2002).
64. Sweeney CJ, Roth BJ, Kabbinavar FF et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J. Clin. Oncol. 24(21), 3451-3457 (2006).
65. Winquist E, Vokes E, Moore MJ et al. A Phase II study of oxaliplatin in urothelial cancer. Urol. Oncol. 23(3), 150-154 (2005).
66. Dreicer R, Li S, Manola J et al. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group. Cancer 110(4), 759-763 (2007).
67. Wülfng C, Machiels JP, Richel DJ et al. A single-arm, multicenter, open-label Phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 115(13), 2881-2890 (2009).
68. Rosenberg JE, Halabi S, Sanford BL et al. Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. Ann. Oncol. 19(5) 946-950 (2008).
69. Petrylak DP, Tangen CM, Van Veldhuizen PJ Jr et al. Results of the Southwest Oncology Group Phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU 105(3), 317-321 (2010).